As a highly interest rate-sensitive stock market segment, biotech stocks have suffered particularly from the rapid rise in interest rates. Until recently, a historically high number of biotech companies were valued "below cash". This was rare before 2021. The phase of irrational undervaluation of biotech companies is coming to an end, what counts again are the fundamentally significant advances in this industry of the future. This is a promising prospect for investors.